Unlike full-length growth hormone, AOD-9604 selectively targets fat metabolism through beta-3 adrenergic receptor pathways without affecting insulin sensitivity or IGF-1 levels
These launches reflect Nestls broader investment in functional food solutions and its strategic focus on the health and medical nutrition sector
When used appropriately and under physician supervision, these medications can provide meaningful short-term progress and support long-term success
Increasingly, people are seeking alternatives to traditional injections, citing convenience and ease of administration as pivotal factors
Additionally, select GLP-1 receptor agonists have received regulatory approval for the treatment of obesity due to their appetite-suppressing and weight-loss-inducing properties
doi: 10.3389/fphar.2025.1557691 Received 09 January 2025 Accepted 19 June 2025 Published 08 July 2025 Volume 16 - 2025 Edited by David Sacerdoti, University of Verona, Italy Reviewed by Ivan oa, University of Rijeka, Croatia Filippo Cattazzo, Integrated University Hospital Verona, Italy Updates Copyright 2025 Tao, Zhang, Wan, Zhao, Chen, Wang, Yang, Wang, Ding, Shang and Zhou
